By Exec Edge Editorial Staff
Ventus Therapeutics said it initiated Phase 1 testing for VENT-02, an orally administered NLRP3 inhibitor with remarkable brain penetration.
The trial with healthy volunteers aims to explore VENT-02’s impact on neuroinflammatory diseases, such as Parkinson’s and Alzheimer’s., with initial findings expected in the first half of 2024, it said in a statement.
“NLRP3 is a key driver of many neuroinflammatory diseases,” said Ventus Chief Scientific Officer Mike Crackower, Ph.D. “Our extensive characterization of VENT-02 in multiple disease-relevant preclinical models has de-risked our disease selection process, and we believe VENT-02 has the potential to treat patients across a wide range of neuroinflammatory diseases, including Parkinson’s, Alzheimer’s, and refractory epilepsy, as well as systemic diseases.”
Contact:
Exec Edge
executives-edge.com
Editor@executives-edge.com
